Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2023 16:05 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 ...
March 15, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023

SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
February 21, 2023 07:00 ET | Source: Evoke Pharma, Inc.

Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session

SOLANA BEACH, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
January 30, 2023 07:00 ET | Source: Evoke Pharma, Inc.

Evoke Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

SOLANA BEACH, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
January 18, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

SOLANA BEACH, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
December 07, 2022 08:30 ET | Source: Evoke Pharma, Inc.

USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe Gastroparesis

SOLANA BEACH, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
November 30, 2022 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®

SOLANA BEACH, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
November 09, 2022 16:05 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Record Third Quarter 2022 Financial Results

80% increase in GIMOTI® net revenue over Q2 202256% increase of GIMOTI prescription fills in Q3 compared to Q213% increase of new prescribers of GIMOTI over Q2 SOLANA BEACH, Calif., Nov. 09, 2022 ...
November 02, 2022 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Report Third Quarter Results on November 9, 2022

SOLANA BEACH, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today...
October 20, 2022 08:44 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Participate in the 2022 American College of Gastroenterology Annual Scientific Meeting

Company will exhibit Gimoti® and meet with Key Opinion Leaders Healio Industry Breakthrough Product Award Nominee SOLANA BEACH, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma,...